Study of SHR-A1912 with other treatments for B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination therapy for adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to see if adding SHR-A1912 to other treatments can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with B-cell non-Hodgkin lymphoma that came back or did not respond to at least one prior therapy.
- You have at least one measurable tumor (larger than about 1.5 cm).
- You are able to take care of yourself (ECOG score 0-1).
- You have not had certain recent treatments like stem cell transplant or Car-T therapy within the past 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SHR-A1912, combined with standard chemotherapy (R-GemOx) for people with diffuse large B-cell lymphoma (DLBCL) that has returned or not improved after at least one prior treatment. It aims to see if the combination works better than chemotherapy alone.
This trial tests a new drug called SHR-3079 for people with B-cell non-Hodgkin lymphoma whose cancer did not get better or came back after at least one standard treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
This trial tests a new drug, SHR2554, for people with follicular lymphoma that has returned or not responded to prior treatments. It aims to see if the drug can shrink tumors and slow the cancer's growth.
This study tests a new therapy called CT1194C for people with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. It aims to see if the therapy is safe and effective.
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
This trial tests two new drugs, SHR-A1921 and SHR-A2009, for people with advanced non-small cell lung cancer that has progressed after prior treatment with an antibody-drug conjugate. The goal is to see if these drugs can shrink tumors and help patients live longer.
Hear when a new B-cell Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.